The Technical Analyst
Vericel Corp [VCEL]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vericel Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.67% $46.11
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 230.82 mill |
| EPS: | -0.0700 |
| P/E: | -658.71 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 48.38 mill |
| Avg Daily Volume: | 0.452 mill |
| RATING 2024-04-24 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -658.71 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -112.06x |
| Company: PE -658.71 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.54 (-92.33%) $-42.57 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 44.47 - 47.67 ( +/- 3.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-17 | Colangelo Dominick | Buy | 17 500 | Stock Option (Right to Buy) |
| 2024-04-18 | Colangelo Dominick | Buy | 17 500 | Stock Option (Right to Buy) |
| 2024-04-18 | Colangelo Dominick | Buy | 17 500 | Common Stock |
| 2024-04-18 | Colangelo Dominick | Sell | 17 500 | Common Stock |
| 2024-04-17 | Colangelo Dominick | Sell | 17 500 | Common Stock |
| INSIDER POWER |
|---|
| 66.18 |
| Last 98 transactions |
| Buy: 842 948 | Sell: 168 823 |
Forecast:
16:00 - $46.11
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $46.11
Forecast 2: 16:00 - $46.11
Forecast 3: 16:00 - $46.11
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $46.11 (-0.67% ) |
| Volume | 0.191 mill |
| Avg. Vol. | 0.452 mill |
| % of Avg. Vol | 42.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VCEL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $45.62 | N/A | Active |
|---|
VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-04-24 08:30:00 - Press Release
Vericel To Report First-quarter 2024 Financial Results On May 8, 2024
Cambridge, mass., april 24, 2024 (globe newswire) -- vericel corporation (nasdaq:vcel), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on wednesday, may 8, 2024. vericel's management will host a conference call and webcast at 8:30 a.m. (et) to discuss its financial results and business highlights.
2024-02-29 07:55:00 - Press Release
Vericel Reports Fourth Quarter And Full-year 2023 Financial Results And Provides Full-year 2024 Financial Guidance
Full-year 2023 total revenue growth of 20% to $197.5 million, with adjusted ebitda growth of 40% fourth quarter total revenue growth of 23% to $65.0 million, with adjusted ebitda growth of 50% fourth quarter gross margin of 75% and adjusted ebitda margin of 34% full-year 2024 total revenue guidance of $237 to $241 million conference call today at 8:30am eastern time cambridge, mass., feb. 29, 2024 (globe newswire) -- vericel corporation (nasdaq:vcel), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the fourth quarter and year ended december 31, 2023, and provided full-year 2024 financial guidance.
2024-02-27 08:30:00 - Press Release
Vericel To Present At The Td Cowen 44th Annual Health Care Conference On Tuesday, March 5, 2024
Cambridge, mass., feb. 27, 2024 (globe newswire) -- vericel corporation (nasdaq:vcel), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that nick colangelo, president and ceo and joe mara, cfo will participate in a fireside chat at the td cowen 44th annual health care conference at 11:10 a.m. et on tuesday, march 5, 2024.
2024-02-15 08:30:00 - Press Release
Vericel To Report Fourth-quarter And Full-year 2023 Financial Results On February 29, 2024
Cambridge, mass., feb. 15, 2024 (globe newswire) -- vericel corporation (nasdaq:vcel), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on thursday, february 29, 2024. vericel's management will host a conference call and webcast at 8:30 a.m. (et) to discuss its financial results and business highlights.
2024-02-05 08:30:00 - Press Release
Vericel To Present At The Canaccord Genuity Musculoskeletal Conference On Monday, February 12, 2024
Cambridge, mass., feb. 05, 2024 (globe newswire) -- vericel corporation (nasdaq:vcel), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that nick colangelo, president and ceo will present at the canaccord genuity musculoskeletal conference. the presentation is scheduled to begin at 11:00 a.m. et (8:00 a.m. pt) on monday, february 12, 2024.
Latest News
2024-04-24 08:30:00 - GlobeNewsWire
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its first-quarter 2024 financial results on Wednesday, May 8, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
2024-02-29 10:06:04 - Zacks Investment Research
Vericel Corporation (VCEL) Q4 Earnings Beat Estimates
Vericel Corporation (VCEL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
2024-02-27 08:30:00 - GlobeNewsWire
Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Tuesday, March 5, 2024.
2024-02-26 11:29:29 - InvestorPlace
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
Pharma stocks and massive potential are synonymous. With horrible diseases like cancer, diabetes, and heart disease still a mile away from developing a cure, drugs that address these conditions command outrageous prices.
2024-02-22 13:01:17 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Vericel Corporation (VCEL) is a Great Choice
Does Vericel Corporation (VCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-15 09:51:24 - Zacks Investment Research
Vericel Corporation (VCEL) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-02-15 08:30:00 - GlobeNewsWire
Vericel to Report Fourth-Quarter and Full-Year 2023 Financial Results on February 29, 2024
CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its fourth-quarter and full-year 2023 financial results on Thursday, February 29, 2024. Vericel's management will host a conference call and webcast at 8:30 a.m. (ET) to discuss its financial results and business highlights.
2024-02-06 10:46:43 - MarketBeat
5 medical stocks growing earnings by triple digits
While most of the market focuses on hyper-growth technology stocks rewarded by Wall Street as long as they mention the word "artificial intelligence" in their earnings calls, the reality is that the fundamentals now favor other (safer) areas of the economy.
2024-02-05 08:30:00 - GlobeNewsWire
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Monday, February 12, 2024
CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday, February 12, 2024.
2024-01-30 09:50:24 - Zacks Investment Research
Recent Price Trend in Vericel Corporation (VCEL) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.